Patent · US Active

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity

US10329277B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignees

Inventors

Yan Zhu · Beijing, CN
Na Zhao · Beijing, CN
Xianxing Shang · Beijing, CN
Yuandong Hu · Beijing, CN
Yong Peng · Beijing, CN
Hui Zhang · Jinan, CN
Bo Liu · Beijing, CN
Hong Luo · Clemson, US
Yongxin Han · Kirkland, CA
Ling Yang · Lianyungang, CN
Hongjiang Xu · Lianyungang, CN

Key dates

Filing date	Jul 15, 2016
Grant date	Jun 25, 2019
Priority date	—
Expiry date	Jul 15, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.